98 related articles for article (PubMed ID: 23376119)
1. p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Montariello D; Troiano A; Malanga M; Calabrò V; Quesada P
Biochem Pharmacol; 2013 Apr; 85(7):999-1006. PubMed ID: 23376119
[TBL] [Abstract][Full Text] [Related]
2. Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Montariello D; Troiano A; Di Girolamo D; Beneke S; Calabrò V; Quesada P
Biochem Pharmacol; 2015 Apr; 94(3):212-9. PubMed ID: 25667043
[TBL] [Abstract][Full Text] [Related]
3. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
4. Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Sabbatino F; Fusciello C; Somma D; Pacelli R; Poudel R; Pepin D; Leonardi A; Carlomagno C; Della Vittoria Scarpati G; Ferrone S; Pepe S
Cytometry A; 2014 Nov; 85(11):953-61. PubMed ID: 25182801
[TBL] [Abstract][Full Text] [Related]
5. Suppression of cell cycle progression by poly(ADP-ribose) polymerase inhibitor PJ34 in neural stem/progenitor cells.
Kurokawa S; Okuda A; Nishizawa Y; Furukawa K; Sumihiro A; Nakaji Y; Tanaka S; Takehashi M
Biochem Biophys Res Commun; 2019 Feb; 510(1):59-64. PubMed ID: 30665718
[TBL] [Abstract][Full Text] [Related]
6. [Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway].
Xiong T; Wei H; Chen X; Xiao H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):312-6. PubMed ID: 24928009
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibitor PJ34 Suppresses Osteogenic Differentiation in Mouse Mesenchymal Stem Cells by Modulating BMP-2 Signaling Pathway.
Kishi Y; Fujihara H; Kawaguchi K; Yamada H; Nakayama R; Yamamoto N; Fujihara Y; Hamada Y; Satomura K; Masutani M
Int J Mol Sci; 2015 Oct; 16(10):24820-38. PubMed ID: 26492236
[TBL] [Abstract][Full Text] [Related]
8. Pifithrin-α enhancing anticancer effect of topotecan on p53-expressing cancer cells.
Guo J; Tang Q; Wang Q; Sun W; Pu Z; Wang J; Bao Y
Eur J Pharm Sci; 2019 Feb; 128():61-72. PubMed ID: 30472223
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor activates the intrinsic pathway of apoptosis in primary lung cancer cells.
Gangopadhyay NN; Luketich JD; Opest A; Landreneau R; Schuchert MJ
Cancer Invest; 2014 Aug; 32(7):339-48. PubMed ID: 24897387
[TBL] [Abstract][Full Text] [Related]
10. The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids.
Koosha F; Neshasteh-Riz A; Takavar A; Eyvazzadeh N; Mazaheri Z; Eynali S; Mousavi M
Biochem Biophys Res Commun; 2017 Sep; 491(4):1092-1097. PubMed ID: 28797568
[TBL] [Abstract][Full Text] [Related]
11. The effect of iodine-131 beta-particles in combination with A-966492 and Topotecan on radio-sensitization of glioblastoma: An in-vitro study.
Koosha F; Eynali S; Eyvazzadeh N; Kamalabadi MA
Appl Radiat Isot; 2021 Nov; 177():109904. PubMed ID: 34454340
[TBL] [Abstract][Full Text] [Related]
12. Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
Kim MK; James J; Annunziata CM
BMC Cancer; 2015 Mar; 15():196. PubMed ID: 25884494
[TBL] [Abstract][Full Text] [Related]
13. PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin.
Mouly L; Mamouni K; Gence R; Cristini A; Cherier J; Castinel A; Legrand M; Favre G; Sordet O; Monferran S
Cell Death Dis; 2018 Sep; 9(9):931. PubMed ID: 30209297
[TBL] [Abstract][Full Text] [Related]
14. Effects of PARP-1 inhibitor and ERK inhibitor on epithelial mesenchymal transitions of the ovarian cancer SKOV3 cells.
Su S; Lin X; Ding N; Zhang H; Zhang Q; Ding Y; Hou X; Tian Y
Pharmacol Rep; 2016 Dec; 68(6):1225-1229. PubMed ID: 27668317
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice.
Huang S; Zhang B; Chen Y; Liu H; Liu Y; Li X; Bao Z; Song Z; Wang Z
J Pharmacol Exp Ther; 2018 Mar; 364(3):452-461. PubMed ID: 29317476
[TBL] [Abstract][Full Text] [Related]
16. Cytoskeletal interference - A new mode of action for the anticancer drugs camptothecin and topotecan.
Wang X; Tanaka M; Krstin S; Peixoto HS; Moura CCM; Wink M
Eur J Pharmacol; 2016 Oct; 789():265-274. PubMed ID: 27474470
[TBL] [Abstract][Full Text] [Related]
17. DNA Damage-Response Pathway Heterogeneity of Human Lung Cancer A549 and H1299 Cells Determines Sensitivity to 8-Chloro-Adenosine.
Yang SY; Li Y; An GS; Ni JH; Jia HT; Li SY
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29843366
[TBL] [Abstract][Full Text] [Related]
18. Intervention timing and effect of PJ34 on astrocytes during oxygen-glucose deprivation/reperfusion and cell death pathways.
Cai C; Zhang R; Huang QY; Cao X; Zou LY; Chu XF
J Huazhong Univ Sci Technolog Med Sci; 2015 Jun; 35(3):397-404. PubMed ID: 26072080
[TBL] [Abstract][Full Text] [Related]
19. Cerebral Vasodilator Property of Poly(ADP-Ribose) Polymerase Inhibitor (PJ34) in the Neonatal and Adult Mouse Is Mediated by the Nitric Oxide Pathway.
Bonnin P; Charriaut-Marlangue C; Pansiot J; Boutigny A; Launay JM; Besson VC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911782
[TBL] [Abstract][Full Text] [Related]
20. PARP1 inhibitor (PJ34) improves the function of aging-induced endothelial progenitor cells by preserving intracellular NAD
Zha S; Li Z; Cao Q; Wang F; Liu F
Stem Cell Res Ther; 2018 Aug; 9(1):224. PubMed ID: 30139380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
